Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.

Zacks Investment Research • Aug 7, 2026

Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts

Celldex Therapeutics remains a "Strong Buy," driven by barzolvolimab's rapid phase 3 enrollment for chronic spontaneous urticaria [CSU] and multiple late-stage catalysts. EMBARQ-CSU 1 and 2 phase 3 trials completed enrollment six months early; pivotal data expected September/October 2026, with potential BLA filing in 2027 if endpoints are met. Company is diversifying with CDX-622, a bispecific TSLP & SCF inhibitor, showing promising safety and mechanism data in phase 1, targeting asthma and other inflammatory disorders.

Seeking Alpha • Jul 26, 2026

Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?

Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.

Zacks Investment Research • Jul 24, 2026

Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss

Celldex Therapeutics NASDAQ: CLDX said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies.

MarketBeat • Jul 22, 2026

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday said it is ending its Phase 2 clinical trial evaluating barzolvolimab for prurigo nodularis, a chronic condition characterized by intensely itchy skin nodules.

Benzinga • Jul 22, 2026

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript

Seeking Alpha • Jul 22, 2026

Celldex to stop skin disease study after trial setback

Celldex Therapeutics said on Tuesday it would discontinue the ​development of its experimental drug for a skin disease ‌after it failed to meet the main goal and key secondary goals in a mid-stage study, sending its shares down over 7% in ​extended trading.

Reuters • Jul 21, 2026

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company's Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (PN), a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin. The primary endpoint of the study, the proportion of patients who achieve a four point or greater improvement in WI-NRS (Worst Itch Numeric Rating Scale) from baseline to Week 12, and key secondary endpoints were not met.

GlobeNewsWire • Jul 21, 2026

Celldex Announces Planned Transition of Chief Financial Officer

HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. Martin has served as the Company's Chief Financial Officer since 2017 and as a member of the Celldex finance team since April 2009. Celldex has initiated a search for a new Chief Financial Officer, and Mr. Martin will remain as the Company's CFO through March of 2027, to support a smooth transition.

GlobeNewsWire • Jul 15, 2026

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex's leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.

GlobeNewsWire • Jun 14, 2026